CSIMarket
 


Northwest Biotherapeutics inc  (NWBO)
Other Ticker:  
 
 

NWBO's Capital Expenditures Growth by Quarter and Year

Northwest Biotherapeutics Inc's Capital Expenditures results by quarter and year




NWBO Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 2.90 1.55 3.06
III Quarter September 0.44 0.00 2.69 2.24
II Quarter June 1.25 0.41 1.51 1.24
I Quarter March 1.33 0.06 0.26 0.06
FY   3.02 3.37 6.01 6.60



NWBO Capital Expenditures third quarter 2023 Y/Y Growth Comment
Northwest Biotherapeutics inc in the third quarter 2023 achieved Capital Expenditures of $ 0.44 millions compare to Capital Expenditures recorded in same quarter a year ago.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Capital Expenditures growth. While Northwest Biotherapeutics Inc' s Capital Expenditures no change of % ranks overall at the positon no. 2095 in the third quarter 2023.




NWBO Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 87.1 % -49.35 % 2681.82 %
III Quarter September - - 20.09 % 11100 %
II Quarter June 204.88 % -72.85 % 21.77 % 1966.67 %
I Quarter March 2116.67 % -76.92 % 333.33 % -62.5 %
FY   - -43.93 % -8.94 % 1785.71 %

Financial Statements
Northwest Biotherapeutics Inc's third quarter 2023 Capital Expenditures $ 0.44 millions NWBO's Income Statement
Northwest Biotherapeutics Inc's third quarter 2022 Capital Expenditures $ 0.00 millions Quarterly NWBO's Income Statement
New: More NWBO's historic Capital Expenditures Growth >>


NWBO Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - -42.38 % 36.61 %
III Quarter September -65.04 % - 78.15 % 80.65 %
II Quarter June -6.02 % 583.33 % 480.77 % 1966.67 %
I Quarter March -54.14 % -96.13 % -91.5 % -45.45 %
FY (Year on Year)   - -43.93 % -8.94 % 1785.71 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #339
Overall #2095

Capital Expenditures Y/Y Growth Statistics
High Average Low
2540.31 % 495.81 % -79.36 %
(Mar 31 2021)   (Sep 30 2022)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #339
Overall #2095
Capital Expenditures Y/Y Growth Statistics
High Average Low
2540.31 % 495.81 % -79.36 %
(Mar 31 2021)   (Sep 30 2022)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Northwest Biotherapeutics Inc's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1906.45 % 83.66 % -100 %
(Jun 30 2020)  


NWBO's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Northwest Biotherapeutics Inc reported fall in Capital Expenditures sequentially by -65.04% to $ 0.44 millions, from $ 1.25 millions achived in the previous quarter.

Within Major Pharmaceutical Preparations industry 169 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Northwest Biotherapeutics Inc's Capital Expenditures growth quarter on quarter, overall rank is 2820.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #170
Healthcare Sector #482
Overall #2820
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #170
Healthcare Sector #482
Overall #2820
Capital Expenditures Q/Q Growth Statistics
High Average Low
1906.45 % 83.66 % -100 %
(Jun 30 2020)  


NWBO's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Northwest Biotherapeutics Inc reported fall in Capital Expenditures from the previous quarter by -65.04% to $ 0.44 millions, from $ 1.25 millions achived in the previous quarter.

Within Major Pharmaceutical Preparations industry 169 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Northwest Biotherapeutics Inc's Capital Expenditures growth quarter on quarter, overall rank is 2820.


Northwest Biotherapeutics Inc's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 5.92 $ 0.00 $ 0.00 $ 0.00 $ 1.55
Y / Y Capital Expenditures Growth (TTM) - - - - -79.36 %
Year on Year Capital Expenditures Growth Overall Ranking # 2175 # 1699 # 1263 # 1390 # 2531
Seqeuential Capital Expenditures Change (TTM) - - - - -67.03 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 2095 # 1534 # 1115 # 1523 # 2811




Cumulative Capital Expenditures growth Comment


In the Healthcare sector 373 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1699 to 2175.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
2540.31 %
495.81 %
-79.36 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 374
Overall # 2175

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2540.31 %
495.81 %
-79.36 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 339
S&P 500 # 2095
Cumulative Capital Expenditures growth Comment


In the Healthcare sector 373 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1699 to 2175.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
2540.31 %
495.81 %
-79.36 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 374
Overall # 2175

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
2540.31 %
495.81 %
-79.36 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 108
Sector # 339
S&P 500 # 2095




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
NWBO's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for NWBO's Competitors
Capital Expenditures Growth for Northwest Biotherapeutics Inc's Suppliers
Capital Expenditures Growth for NWBO's Customers

You may also want to know
NWBO's Annual Growth Rates NWBO's Profitability Ratios NWBO's Asset Turnover Ratio NWBO's Dividend Growth
NWBO's Roe NWBO's Valuation Ratios NWBO's Financial Strength Ratios NWBO's Dividend Payout Ratio
NWBO's Roa NWBO's Inventory Turnover Ratio NWBO's Growth Rates NWBO's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com